Navigation Links
KEW Group Launches CancerPlex(SM) Assay to Bring State-of-the-Art Genomic Testing to Community Oncologists
Date:10/25/2013

CAMBRIDGE, Mass., Oct. 25, 2013 /PRNewswire/ -- KEW Group Inc. (KEW), a privately held oncology services company located in Cambridge, Mass., announced today the launch of CancerPlexSM, a highly versatile and comprehensive gene testing panel to evaluate genetic changes in a patient's tumor to help oncologists effectively manage treatment options. CancerPlexSM was developed and validated in KEW's CLIA laboratory and can be used for examination of the genetic profile of many common cancers.

KEW Group is also developing state-of-the-art evidence-based therapeutic pathways that provide information about when it is appropriate to conduct diagnostic testing, including molecular diagnostics, and how that information can be used in clinical decision support.

"With the addition of the KEW CancerPlexSM, we are providing an important new service to community oncologists by incorporating state-of-the art genomic testing with evidence-based diagnostic and treatment pathways to benefit cancer patients," said Kathy Behrens Wilsey, CEO of KEW Group Inc.  "These services are expected to provide the basis for both current and next generation cancer treatments."

KEW's CancerPlexSM assay utilizes next-generation sequencing to analyze more than 400 known cancer genes involved in cancer initiation and progression. The resulting information from this tumor mutation analysis can be used by physicians to supplement other patient-specific information and assist in the determination of treatment options.

About KEW Group Inc.

KEW Group Inc. provides multiple services to oncologists to assist in treatment decisions for cancer patients: genomic testing for patient tumor samples (KEW MDx) and providing genomic information important to diagnostic and treatment decisions that assist physicians and are detailed in cancer-specific Therapeutic Pathways (KEW TPx). KEW MDx's CancerPlexSM test is the first of its diagnostic services designed to assist community oncologists in providing state-of-the-art genomic testing that previously has been available at large cancer treatment and academic centers. KEW is currently working with seven oncology practices in six different states to refine Therapeutic Pathways for seven types of cancer (breast, colorectal, lung, melanoma, lymphoma, thyroid and pancreatic). These seven practices all participate in a Center for Medicare and Medicaid Innovation Grant, which is developing and testing a Community Oncology Medical Home model, known as COME HOME. The grant is administered through Innovative Oncology Business Solutions, Inc., the organization that oversees and manages COME HOME. KEW's Treatment Pathways integrate newly emerging cancer genomic information that follows evidence standards essential to how and when to perform molecular tests, as well as inform care decisions. 

KEW Investor Contact:
Kathy Behrens Wilsey
Kathy@kewgroupllc.com


'/>"/>
SOURCE KEW Group Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Consolidation, Patent Loses, Weak R&D Productivity Depress ITO Transactions in Life Sciences Segment: Everest Group Annual Report
2. Polaris Group Files New IND for ADI-PEG 20 in Breast Cancer
3. WIRB-Copernicus Group Leaders Speak at Global Clinical Research Summit in South Korea
4. Global Stem Cells Group, Inc. Announces Worldwide Alliance with EmCyte Corp. to Promote In-office Regenerative Medicine Solutions
5. FarHawk Marketing Services Represents IonBench™ and MS Noise™ at the Greater Boston Mass Spectrometry Discussion Group Corporate Night October 3rd
6. Reimbursement Marketing Agency Element Marketing Group Inc. Opens New Office in Irvine, California
7. Dennis R. Hill, MD to Speak at the American Cancer Society Man-to-Man Support Group to Discuss HDR Brachytherapy for Prostate Cancer Treatment
8. Bangkok Hospital Group Selects ClinicalKey to Enhance Medical Practice and Improve Patient Care
9. The Arrow Group of Animal Hospitals in Central Arizona Partners with Vet-Stem, Inc. to Bring Stem Cell Therapy to Their Patients
10. Dennis R. Hill, MD to Speak at the American Cancer Society Man-to-Man Support Group to Discuss HDR Brachytherapy for Prostate Cancer Treatment
11. RGF Environmental Group Acquires AFL Industries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of 8.5 ... end machines that use the more unconventional z-dimension of 20mm. Z-dimension or ... the cuvette holder. , FireflySci has developed several Agilent flow cell product lines ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, ... microbial test has received AOAC Research Institute approval 061601. , “This is another ... year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry Network for ... Design Lab . Located in Pasadena, Calif., the Design Lab’s mission is to ... are designed, built and brought to market. , The Design Lab is Supplyframe’s ...
Breaking Biology Technology:
(Date:4/28/2016)... India , April 28, 2016 ... Infosys (NYSE: INFY ), and Samsung SDS, a ... that will provide end customers with a more secure, ... services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... services, but it also plays a fundamental part in enabling ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
(Date:3/31/2016)... -- Genomics firm Nabsys has completed a financial  restructuring under ... M.D., who returned to the company in October 2015. ... including Chief Technology Officer, John Oliver , Ph.D., ... Vice President of Software and Informatics, Michael Kaiser ... Bready served as CEO of Nabsys from 2005-2014 and ...
Breaking Biology News(10 mins):